Karuna Therapeutics, Inc. (KRTX): Price and Financial Metrics


Karuna Therapeutics, Inc. (KRTX)

Today's Latest Price: $98.99 USD

1.19 (-1.19%)

Updated Jul 8 4:00pm

Add KRTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

KRTX Daily Price Range
KRTX 52-Week Price Range

KRTX Stock Price Chart Technical Analysis Charts


KRTX Price/Volume Stats

Current price $98.99 52-week high $152.00
Prev. close $100.18 52-week low $11.24
Day low $96.68 Volume 147,129
Day high $100.11 Avg. volume 332,163
50-day MA $92.96 Dividend yield N/A
200-day MA $70.99 Market Cap 2.59B

Karuna Therapeutics, Inc. (KRTX) Company Bio


Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company develops treatments for people afflicted with schizophrenia. Karuna Therapeutics was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.


KRTX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

KRTX Latest Social Stream


Loading social stream, please wait...

View Full KRTX Social Stream

Latest KRTX News From Around the Web

Below are the latest news stories about Karuna Therapeutics Inc that investors may wish to consider to help them evaluate KRTX as an investment opportunity.

Hedge Funds Keep Buying Karuna Therapeutics, Inc. (KRTX)

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

Yahoo | June 28, 2020

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Insiders Increased Their Holdings

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

Yahoo | June 24, 2020

Karuna to advance lead drug into Phase 3 for psychosis in schizophrenia patients

Fresh off a meeting with the FDA, Karuna Therapeutics (KRTX) will advance lead candidate KarXT into Phase 3 development for the treatment of acute psychosis in patients with schizophrenia.The agency is on board with one successful late-stage study, along with additional safety data and results from previously generated trials, to...

Seeking Alpha | June 23, 2020

Karuna Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for KarXT for the Treatment of Acute Psychosis in Patients with Schizophrenia

Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced next steps in the clinical program evaluating KarXT for the treatment of acute psychosis in patients with schizophrenia following the completion of a successful End-of-Phase 2 meeting with the U.S. Food & Drug Administration (FDA). The outcome of the meeting supports the progression of KarXT into Phase 3 development. The Company remains on track to initiate the Phase 3 program by the end of 2020.

Yahoo | June 23, 2020

Karuna Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna Therapeutics, will participate in a fireside chat at the virtual Goldman Sachs Annual Global Healthcare Conference

Business Wire | June 3, 2020

Read More 'KRTX' Stories Here

KRTX Price Returns

1-mo 1.48%
3-mo 44.93%
6-mo 37.16%
1-year 321.05%
3-year N/A
5-year N/A
YTD 31.39%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8574 seconds.